New knowledge on Eli Lilly’s weight-loss drug reveals its outlook is shiny

Eli Lilly’s office in La Jolla, California.

Konrad Fiedler | Bloomberg | Getty Images

The launch of Eli Lilly‘s weight-loss drug Zepbound — a key pillar of our investment thesis in the pharmaceuticals giant — is going swimmingly in the U.S., Jefferies said Friday.

Comments are closed.